ImmunoPrecise Antibodies Ltd. is a public company listed on the TSX Venture Exchange (TSXV: IPA) located in Victoria, British Columbia, Canada and preeminent supplier of custom antibodies to the global research industry and industrial community. Our dedication to advancing antibody development has resulted in cutting-edge immunological innovations. With over 25 years of experience in the custom antibody business, ImmunoPrecise provides high customer satisfaction through a customized professional approach.
ImmunoPrecise is comprised of experienced research and development scientists and encompasses a wide range of distinctive competencies, including innovative technologies required in the production of monoclonal and polyclonal antibodies. We pride ourselves on our high customer satisfaction and our clients have grown accustomed to receiving very thorough and professional service. We customize your project to generate antibodies that meet your specific needs. Our clients include: scientists in the biotech and pharmaceutical sector, academic researchers and those employed by government.
Since its inception in 1989, ImmunoPrecise has been serving clinical research and biological markets worldwide. With its beginnings in the Biochemistry/Microbiology department at the University of Victoria, ImmunoPrecise expanded and built a new Hybridoma Facility, at the Vancouver Island Technology Park (VITP) in 2005.
Robert Beecroft, Chief Technical Officer and Founder, has implemented 3 key methodologies that have allowed ImmunoPrecise to be set apart from other antibody companies: 1) the Rapid Prime immunization strategy in mice; 2) Single-Step cloning for HAT selection of hybridomas and 3) B-cell Selection- recombinant monoclonal antibody technology for the generation of rabbit, rodent, and human monoclonal antibodies.
ImmunoPrecise uses proprietary and innovative inoculation and cloning technologies and established expertise to produce mAbs significantly faster than traditional methods of antibody production and has used these capacities to produce hundreds of mAbs, many of which are now being sold commercially through industry partners.
Our state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia house a Canadian Council for Animal Care (CCAC) animal care unit, tissue culture, and a B cell facility. ImmunoPrecise operates globally to offer antibody services from target analysis to pre-clinical lead generation, in collaboration with our subsidiary operations at U-Protein Express B.V., Utrecht, and ModiQuest Research B.V., Oss, both in the Netherlands.
ImmunoPrecise offers a selection of high quality antibody products to the research and industrial community. For further details, please view our complete list of antibodies.
ImmunoPrecise is increasing its panel of antibodies specifically for out-licensing.
ImmunoPrecise’s proprietary technologies and products are positioned on the leading edge of antibody development, innovating our industry as a single source provider of the full compliment of antibody discovery platforms. As an investor in ImmunoPrecise Antibodies, you’re joining us at the forefront of new, exciting, and valuable advancements in next-generation antibody discovery.
For investor inquiries please contact:
+1 (438) 863-7071,
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated twenty five hundred dollars for ImmunoPrecise Antibodies Ltd. current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF ImmunoPrecise Antibodies Ltd.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.